18 completed, 3 unknown, 2 active not recruiting, 2 terminated. 8 Phase 4, 5 Phase 1, 4 Not applicable, 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 8 | Completed 6, Unknown 2 |
| Phase 1 | 5 | Completed 5 |
| Not applicable | 4 | Active not recruiting 2, Completed 2 |
| Phase 3 | 3 | Completed 2, Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Desvenlafaxine: new trials by email Literature Review of Desvenlafaxine trials Research Report on Desvenlafaxine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Desvenlafaxine for Preventive Treatment of Frequent Migraines Desvenlafaxine, Placebo - Migraine | Not applicable | Active not recruiting | Tongji Hospital | 440 | 2026-01-01 | 2026-02-04 |
| Desvenlafaxine for Preventive Treatment of Frequent Episodic Tension-type Headache Desvenlafaxine, Placebo - Tension Type Headache | Not applicable | Active not recruiting | Tongji Hospital | 432 | 2025-12-01 | 2026-01-22 |
| A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats Fezolinetant, Paroxetine, Citalopram - Hot Flashes | Completed | Astellas Pharma Global Development, Inc. | 999 | 2023-11-15 | 2026-06-05 | |
| Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea Escitalopram, Paroxetine, Fluoxetine - Major Depression | Completed | Pfizer | 370212 | 2022-07-04 | 2024-12-09 | |
| A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder SAGE-217, Matching Placebo, Sertraline - Depressive Disorder, Major | Phase 3 | Completed | Biogen | 440 | 2020-11-09 | 2023-12-22 |
| Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression Vortioxetine, Desvenlafaxine - Major Depressive Disorder | Phase 4 | Completed | H. Lundbeck A/S | 605 | 2020-06-18 | 2022-02-14 |
| A Relative Bioavailability Food Effect Study of LY03005 LY03005 - Major Depressive Disorder | Phase 1 | Completed | Luye Pharma Group Ltd. | 34 | 2019-01-16 | 2019-08-06 |
| A Study of LY03005 vs Pristiq LY03005, Pristiq - Major Depressive Disorder | Phase 1 | Completed | Luye Pharma Group Ltd. | 56 | 2018-06-19 | 2018-11-09 |
| Switching From SSRI to Desvenlafaxine on Cognitive Functioning Desvenlafaxine - Major Depressive Disorder | Unknown | Corporacion Parc Tauli | 36 | 2018-04-03 | 2019-04-18 | |
| Relative Bioavailability (RBA) Study of LY03005 vs Pristiq® LY03005, Pristiq - Major Depressive Disorder | Phase 1 | Completed | Luye Pharma Group Ltd. | 20 | 2017-11-27 | 2018-01-04 |
| Dimensional Approach to Evaluate Reward Processing in Major Depressive Disorder Pre- and Post-Desvenlafaxine Treatment Desvenlafaxine - Depression, Anhedonia | Phase 4 | Completed | Unity Health Toronto | 56 | 2017-06-01 | 2020-11-02 |
| Pilot BA Study of New LY03005 vs Pristiq LY03005, Pristiq - Major Depression | Phase 1 | Completed | Luye Pharma Group Ltd. | 20 | 2016-12-07 | 2017-03-20 |
| Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies Lithium Carbonate, Lamotrigine, Valproic Acid - Bipolar Disorder | Terminated | University of New Mexico | 1037352 | 2016-09-01 | 2024-03-12 | |
| Prediction of Antidepressant Treatment Response Using Machine Learning Classification Analysis Desvenlafaxine, Placebo - Major Depressive Disorder | Phase 4 | Unknown | University of Calgary | 61 | 2014-12-01 | 2015-01-05 |
| Desvenlafaxine in Opioid-Dependent Patients Desvenlafaxine - Depression, Opioid Dependence | Phase 4 | Completed | Centre hospitalier de l'Université de Montréal (CHUM) | 18 | 2014-07-01 | 2020-10-23 |
| Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury Duloxetine, Venlafaxine, Desvenlafaxine - Depression, Acute Kidney Injury | Completed | Canadian Network for Observational Drug Effect Studies, CNODES | 3255526 | 2013-06-01 | 2016-03-14 | |
| Omega 3 FA Supplements as Augmentation in the Treatment of Depression Desvenlafaxine, Omega 3 Fatty acids, Placebo (for Omega 3 fatty acid supplement) - Major Depression, Cancer | Phase 2 / Phase 3 | Terminated | UConn Health | 6 | 2013-02-01 | 2017-12-27 |
| Efficacy of SNRI Treatment on Prefrontality in Patients With GAD and Other Comorbities Desvenlafaxine - Generalized Anxiety Disorder | Phase 4 | Completed | START Clinic for Mood and Anxiety Disorders | 29 | 2013-01-01 | 2020-10-23 |
| Desvenlafaxine Monotherapy in Dysthymia Desvenlafaxine - Dysthymic Disorder | Not applicable | Completed | Centre for Addiction and Mental Health | 30 | 2012-08-01 | 2014-11-07 |
| Desvenlafaxine vs. Placebo Treatment of Chronic Depression Desvenlafaxine, Placebo - Dysthymic Disorder, Dysthymia | Phase 4 | Completed | New York State Psychiatric Institute | 59 | 2012-02-01 | 2017-09-11 |
Showing 20 of 25. Sign in to see all of them.
Depressive Disorder, Major (14) · Depression (6) · Depressive Disorder (3) · Mental Disorders (3) · Mood Disorders (3) · Dysthymic Disorder (2) · Generalized Anxiety Disorder (2) · Phobia, Social (2) · Acute Kidney Injury (1) · Anhedonia (1) · Anxiety Disorders (1) · Behavior, Addictive (1) · Bipolar Disorder (1) · Cardiovascular Diseases (1) · Diabetes Mellitus (1)
Luye Pharma Group Ltd. (4) · Pfizer (2) · Tongji Hospital (2) · Astellas Pharma Global Development, Inc. (1) · BC Women's Hospital & Health Centre (1) · Biogen (1) · Canadian Network for Observational Drug Effect Studies, CNODES (1) · Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal (1) · Centre for Addiction and Mental Health (1) · Centre hospitalier de l'Université de Montréal (CHUM) (1) · Corporacion Parc Tauli (1) · H. Lundbeck A/S (1) · New York State Psychiatric Institute (1) · START Clinic for Mood and Anxiety Disorders (1) · The Medical Research Network (1)
United States (10) · Canada (9) · China (2) · South Korea (2) · Spain (2) · Argentina (1) · Belgium (1) · Bulgaria (1) · Czechia (1) · Estonia (1) · Latvia (1) · Mexico (1) · Russia (1) · Slovakia (1) · Sweden (1)
Amy Sun, MD, PhD, MBA (2) · Wensheng Qu (2) · Arun Ravindran, MD, PhD (1) · Christophe G Lambert, PhD (1) · David J Hellerstein, MD (1) · Didier Jutras-Aswad, M.D., M.Sc. (1) · Jayesh Kamath, MD PhD (1) · Julie Bruneau, M.D., M.Sc. (1) · Kevin Booth, MD, DVM (1) · Michael R. Liebowitz, MD (1)
PMID 26231193, PMID 27280963, PMID 28763344, PMID 28901625, PMID 29738425, PMID 29920885, PMID 30423468, PMID 30583256, PMID 30986735, PMID 31237566, PMID 31651956, PMID 31744781, PMID 33688834, PMID 35592490, PMID 36996664, PMID 37227402, PMID 37875578, PMID 40108685, PMID 40456468, PMID 42214294